BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

International Wex Technologies (WXI) Release: Regulatory Approval For An Open Label Clinical Trial


10/19/2005 5:10:54 PM

International Wex Technologies Inc. ("Wex" or the "Company") is pleased to announce that it received regulatory approval (No Objection Letter) from Health Canada, on April 8, 2004, for initiating an Open-Label extension Clinical Trial for Tectin(TM) in patients with moderate to severe cancer-related pain. This multi-centre, safety and efficacy study is a long-term continuation of the current Pivotal Phase IIb/III trial that is underway and will be run in parallel. In an effort to enforce Wex's commitment to improving quality of life the Company requested this study in order to make Tectin(TM) available to all patients who participate in the Pivotal Phase IIb/III trial. This will allow the patients who obtained benefit from the drug as well as those who received placebo to obtain Tectin(TM) for continued treatment while providing the Company with data on the long-term safety and efficacy of the product. This would preclude preventing or delaying patients benefiting from continued treatment before product commercialization.

Read at CCNMatthews

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES